Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
UDG Healthcare shares press ahead and the dividend is back

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
UDG Healthcare (UDG) 721.2p
Gain to date: 3.9%
Original entry point: Buy at 694p, 16 July 2020
Our bullish stance on healthcare support services firm UDG Healthcare (UDG) is off to a decent start.
On 5 August the company reinstated its dividend and resumed earnings guidance as visibility on trading improved. The company declared an unchanged first-half dividend for the six months through March of 4.46 cents per share.
A decision to pay a final dividend for the financial year which ends on 30 September remains under review.
UDG says it expects to post adjusted diluted earnings per share for the year of between 43 cents and 45 cents.
Pre-tax profit on a constant currency basis for the first nine months of the year is expected to be ahead of the prior year.
UDG has two divisions: Ashfield provides advisory, communications and commercialisation services while Sharp is a leader in contract clinical trials, manufacturing and packaging.
Numis analyst Paul Cuddon says: ‘On the one hand, Sharp has benefited from increased outsourcing as a consequence of in-house staffing/packaging constraints, whilst Ashfield has been impacted by the disruption to healthcare services in the US and Europe.’
SHARES SAYS: An encouraging start, still a buy.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.
Our website uses cookies to give you a better browsing experience.
You can choose to accept all cookies, or control which we use by clicking 'Manage cookies'. To learn more, read our cookie policy.